CLRB
Cellectar Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.37
+0.85%Aug 13, 2026, 18:57 UTC
Cellectar Biosciences, Inc. held its Q2 2026 earnings call on August 13, 2026.
Source:Aug 13, 2026, 00:00 UTC
Cellectar Biosciences announced a securities offering with aggregate upfront proceeds of approximately $35 million and potential milestone-based proceeds of up to $105 million.
Jul 15, 2026, 11:30 UTC
Cellectar Biosciences announces the publication of a Phase 1 study of Iopofosine I 131 in the peer-reviewed journal Cancers.
Source: